BioAge is developing BGE-117, a drug that inhibits an enzyme responsible for breaking down Hypoxia-Inducible Factor (HIF). Increased amounts of HIF in the bloodstream are associated with blood cell production, glucose metabolism, and vascular remodeling.
The company is engaging in a Phase 2a trial of this drug against unexplained anemia, a disorder that affects older people and reduces their red blood cell counts for reasons that, as of yet, are not understood. In this Australian study, which will be conducted at 15 sites, an oral dose of BGE-117 will be given to 80 patients (with an additional 80 receiving a placebo) daily for 12 weeks.
This trial’s endpoints will be hemoglobin levels and self-reported results on the FACIT-F scale, which evaluates the effects of fatigue on daily life. Other biomarkers and muscle aging will also be measured.
BioAge has also initiated a Phase 2 trial of BGE-175, an oral inhibitor of prostaglandin D2 (PGD2) DP1 signaling, for COVID-19 by reversing immune aging by inhibiting neutrophil migration and boosting dendritic cell function.
In addition, BioAge has licensed, as per a press release, an AJP agonist for muscle wasting, BGE-105, from Amgen and plans to initiate a Phase 1 trial in 2022.